S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.79%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.79%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.79%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.79%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)

UnitedHealth Group For Healthy Dividend Growth Portfolios

UnitedHealth Group For Healthy Dividend Growth Portfolios

UnitedHealth Is A Buy On Post-Earnings Weakness

Shares of UnitedHealth NYSE: UNH are down in the wake of the Q2 earnings release but this is an opportunity for investors to get some more of these shares at a discounted price. The move is driven, in our opinion, by the expected year-over-year decline in earnings caused by COVID so shouldn't last long. While the company's revenue is on the rise its medical care ratio is also on the rise and cutting into profits. What investors need to focus on is the fact that medical care expenses were in line with the consensus estimate and the peak of COVID is now well behind us. As we move forward, we expect medical care costs to begin falling sharply in the third quarter and drive improved profitability in the second half of the year.

United Health Beats And Raises, Shares Fall

UnitedHealth had a great quarter and we can't fault it for the increase in medical care costs. As a healthcare insurer, it is uniquely positioned to incur costs related to the pandemic. Things could have been worse. That said, the company's $71.30 billion in consolidated revenue is up 14.7% from last year and beat the consensus by 250 basis points. This is also the fourth quarter of sequential revenue gains and revenue is up 17.7% from the same time frame two years ago. On a segment basis, the company experienced double-digit gains in both the Optum and UnitedHealth arms of the business. UnitedHealth saw revenue increase 13% while Optum leads with an increase of 17.2%.


Moving down towards profitability metrics, the company's Medical Care ratio surged 12.6% to 82.8% over the past year but came in roughly in line with the consensus of 82.7%. As for operating cost, the operating cost ratio of 14.5% matches the consensus exactly. The bad news is that adjusted and GAAP earnings fell in the range of 35% from last year, the good news is that GAAP EPS of $4.46 and the adjusted EPS of $4.70 both beat the consensus by a quarter dollar.

Looking forward, the company is expecting earnings to improve if not for revenue and has raised its guidance for both GAAP and adjusted EPS. UnitedHealth is now expecting an adjusted EPS of $18.3 to $18.80 versus the prior $17.15 to $17.65 with a similar increase to the GAAP guidance. This compares to the consensus estimate of $18.58 and we think that it is conservative guidance. Results in the first half of the year are already worth 55% of the guidance and we are expecting revenue strength to continue as well as improved profitability.

UnitedHealth Has Got A Healthy Dividend Outlook

United Health is not one of the higher-yielding dividend growth stocks that we follow but it is among the safest and comes with a very attractive growth outlook. At current price levels, the stock is yielding about 1.4% but comes with a 31% payout ratio, 12 years of increases, and a 20% distribution CAGR. The last increase was worth 16% so it's possible the pace of distribution increases will slow but that is offset by better-than-expected earnings. In our view, investors should be looking for a 15 to 20% increase when the distribution is raised again at the end of the fiscal year. And the balance sheet is a fortress so there's no worry there.

The Technical Outlook: UnitedHealth Stumbles Into A Buying Opportunity

Shares of UnitedHealth fell in the wake of the Q2 earnings release but investors are already scooping up the deal. Early price action moved down to test support at the short-term moving average and support is already kicking in. At this time, it looks like a nice trend-following bounce is in play, the only caveat is that this candle has yet to close so price action could look much different by the end of the day. Assuming the stock closes near the high of the session, we see this stock Moving at the set a new all-time high very soon. 

UnitedHealth Group For Healthy Dividend Growth Portfolios

→ 66,000% upside on tiny biotech? (From Behind the Markets) (Ad)

Should you invest $1,000 in UnitedHealth Group right now?

Before you consider UnitedHealth Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.

While UnitedHealth Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
UnitedHealth Group (UNH)
4.9808 of 5 stars
$521.97+0.2%1.44%21.89Moderate Buy$575.79
Compare These Stocks  Add These Stocks to My Watchlist 

Thomas Hughes

About Thomas Hughes

  • tmhughes.writeon@gmail.com

Contributing Author

Technical and Fundamental Analysis

Experience

Thomas Hughes has been a contributing writer for MarketBeat since 2019.

Areas of Expertise

Technical analysis, the S&P 500; retail, consumer, consumer staples, dividends, high-yield, small caps, technology, economic data, oil, cryptocurrencies

Education

Associate of Arts in Culinary Technology

Past Experience

Market watcher, trader and investor for numerous websites. Founded Passive Market Intelligence LLC to provide market research insights. 


Featured Articles and Offers

Search Headlines: